Pharma Giants Bypass US Regulations: Global Drug Trials Operating in Xinjiang Escape Scrutiny

Multinational pharmaceutical giants are reportedly continuing drug research and human trials in China’s Xinjiang region, seemingly bypassing stringent U.S. regulations. These activities include R&D investments and clinical testing conducted at Xinjiang and at People’s Liberation Army (PLA) affiliated sites.

According to an article by The Wire, data compiled using resources from ClinicalTrials.gov, a US National Library of Medicine database, indicates that international firms have long sponsored medical trials in the region. The reports highlight the continuing operation of these tests despite severe regulatory and human rights concerns.

Persistent Testing Operations in Xinjiang​

The true scope of drug testing conducted in Xinjiang and associated military hospitals remains challenging to measure accurately. ClinicalTrials.gov requires registered trials to follow regional authority rules, but the system is not comprehensive.

Data indicates that some trials only list the city where the tests occurred, omitting specific hospital identification. Furthermore, the PLA maintains 165 hospitals across each of China’s provinces, and these military facilities do not always openly identify their armed forces affiliation.

Industry Model: Using Diverse Data Points​

Operating trials at multiple, varied locations allows pharmaceutical companies to gather extensive data. This data tracks how specific medicines impact diverse populations under various real-world conditions.

Ultimately, these comprehensive results are vital for companies seeking final approval from regulatory agencies to market their products globally. The article cited the case of AstraZeneca’s Covid-era treatment, Evusheld, which was trialed in Xinjiang alongside sites across the United States, Europe, Latin America, and Japan.

Regulatory Exemptions and U.S. Oversight Gaps​

This industry model shows how pharmaceutical firms can market products in the United States while operating in Xinjiang, often without facing regulatory requirements related to forced labour concerns. This operates despite warnings from several foreign governments and the United Nations regarding human rights violations in the region.

The breakthrough factor appears to be regulatory exemptions. Unlike technology or agricultural firms, drug manufacturers were exempt from sanctions passed under the Uyghur Forced Labor Prevention Act (UFLPA). This act, implemented in 2021, generally prevents the import of goods mined, produced, or manufactured in Xinjiang unless a forced labour-free supply chain is proven.

Congressional Scrutiny Over Uninspected Sites​

The lack of adequate oversight has drawn severe attention, prompting the House of Representatives’ bipartisan Select Committee on the Chinese Communist Party to address the FDA in 2024. The committee demanded more information regarding pharmaceutical trials conducted in Xinjiang and at PLA hospitals.

The committee chairman, John Moolenaar (R-MI), stated that China runs trials at PLA military hospitals and in Xinjiang, pointing to a documented history of people being coerced into medical studies amid the CCP's actions against Uyghur Muslims and other minorities. Moolenaar further highlighted that the FDA currently allows companies to advance drug applications in the United States using data from uninspected Chinese trial sites.